06
Sep

Strata Oncology, Inc. today announced it is participating as a CLIA-certified/accredited laboratory for the precision medicine cancer trial, NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131). The objective of this ongoing phase II trial, co-led by the National Cancer Institute (NCI), part of the National Institutes of Health, and the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), is to match genetic abnormalities of tumors with suitable targeted therapy, regardless of cancer type.
Link

0 Comments

Comments are closed.